查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1604899

中軸型脊椎關節炎市場：按類型、藥物類別（抗風濕藥、糖皮質激素、非類固醇消炎劑）、最終用戶分類 - 2025-2030 年全球預測

Axial Spondyloarthritis Market by Type (Ankylosing Spondylitis, Non-Radiographic Axial Spondyloarthritis )), Drug Class (Anti-Rheumatic Drugs, Glucocorticoids, Non-steroidal anti-inflammatory Drugs ), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年中軸型脊椎關節炎市值為53.2億美元，預計2024年將達56.8億美元，複合年成長率為7.42%，預計到2030年將達到87.9億美元。

中軸型脊椎關節炎 (axSpA) 是一種慢性發炎疾病，主要影響脊椎和骶髂關節，導致疼痛和進行性僵硬。推進 axSpA 研究的必要性源於該疾病患病率的不斷上升、認知不足以及對更有效治療方法的需求。最終用途包括醫療設施、研究機構和製藥公司。影響市場成長的主要因素包括疾病意識的提高、診斷影像的進步以及生技藥品和生物相似藥的推出。此外，遺傳和環境因素在 axSpA 發病機制中的強烈參與導致人們對個人化醫療的興趣日益濃厚，為客製化治療創造了機會。對新型生物製藥（包括 IL-17 和 JAK 抑制劑）的研究正在進行中，並提供了潛在的成長途徑，同時透過基因分析和生物標記發現改進了治療的個體化。然而，該市場也存在局限性，包括治療成本高、生物製藥潛在的副作用以及早期診斷的複雜性。此外，這種疾病的慢性性質給醫療保健系統帶來了壓力，凸顯了對具有成本效益的管理解決方案的需求。進入該市場的公司正在投資開拓副作用較少的創新藥物，加強對醫療保健提供者和患者的教育和宣導活動，並評估治療的長期有效性和安全性，需要在臨床試驗中合作。監測疾病進展的數位健康工具、人工智慧在診斷準確性方面的整合以及非侵入性治療方法的開發等領域的創新可能會蓬勃發展。因此，雖然 axSpA 市場面臨挑戰，但它也提供了切實的突破機會，可以重新定義患者照護和市場動態。

主要市場統計
基準年[2023] 53.2億美元
預測年份 [2024] 56.8億美元
預測年份 [2030] 87.9億美元
複合年成長率（%） 7.42%

市場動態：快速發展的中軸型脊椎關節炎市場的關鍵市場洞察

供需的動態交互作用正在改變中軸型脊椎關節炎市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 關節炎和關節疼痛加劇
    • 增加研發活動
    • 政府和私人公司努力擴大關節炎的治療選擇
  • 市場限制因素
    • 產品或藥品召回的發生
  • 市場機會
    • 中軸型脊椎關節炎個人化治療進展
    • 針對中軸型脊椎關節炎的新型生物製藥的出現
  • 市場挑戰
    • 嚴格醫藥品認證過程規定

波特五力：駕馭中軸型脊椎關節炎市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解中軸型脊椎關節炎市場的外部影響

外部宏觀環境因素在塑造中軸型脊椎關節炎市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解中軸型脊椎關節炎市場的競爭格局

對中軸型脊椎關節炎市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣中軸型脊椎關節炎市場供應商的績效評估

FPNV 定位矩陣是評估中軸型脊椎關節炎市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了中軸型脊椎關節炎市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對中軸型脊椎關節炎市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 關節炎和關節痛的發生率增加
      • 增加研發活動
      • 政府和私人努力擴大關節炎的治療選擇
    • 抑制因素
      • 產品和藥品回收數量
    • 機會
      • 中軸型脊椎關節炎個人化照護的進展
      • 治療中軸型脊椎關節炎的新生物製藥的出現
    • 任務
      • 嚴格藥品核准流程規定
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章中軸型脊椎關節炎市場：依類型

  • 僵直性脊椎炎（AS）
  • 非放射性中軸型脊椎關節炎 (nr-axSpA)

第7章中軸型脊椎關節炎市場：依藥物類別

  • 抗風濕藥
  • 糖皮質激素
  • 非類固醇消炎劑(NSAID)

第 8 章 中軸型脊椎關節炎市場：依最終使用者分類

  • 學術研究所
  • 診所
  • 醫院
  • 復健中心

第9章北美和南美中軸型脊椎關節炎市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太中軸型脊椎關節炎市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的中軸型脊椎關節炎市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Eli Lilly and Company
  • Galapagos NV
  • Inmagene Biopharmaceuticals
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • UCB SA
Product Code: MRR-5C6F41F5AF7D

The Axial Spondyloarthritis Market was valued at USD 5.32 billion in 2023, expected to reach USD 5.68 billion in 2024, and is projected to grow at a CAGR of 7.42%, to USD 8.79 billion by 2030.

Axial Spondyloarthritis (axSpA) is a spectrum of chronic inflammatory diseases primarily affecting the spine and the sacroiliac joints, leading to pain and progressive stiffness. The necessity of advancing research in axSpA stems from the increasing prevalence of the condition, inadequate awareness, and a demand for more effective treatments. Applications include improving diagnostic methods, refining therapeutic interventions, and tailored patient management to enhance quality of life, while end-use scope is seen in healthcare facilities, research institutes, and pharmaceutical companies. Key factors influencing market growth include rising awareness about the disease, advances in diagnostic imaging, and the introduction of biologics and biosimilars. Furthermore, the significant role of genetic and environmental factors in axSpA's etiology has stimulated interest in personalized medicine, creating opportunities for tailored therapeutics. Ongoing research into novel biologics, including IL-17 and JAK inhibitors, represents potential growth avenues, alongside improved treatment personalization through genetic profiling and biomarker exploration. Nonetheless, market limitations include high treatment costs, potential side effects of biologics, and the complexities of early diagnosis. Additionally, the chronic nature of the disease burdens healthcare systems, highlighting a need for cost-effective management solutions. Entities in this market are urged to invest in the development of innovative drugs with fewer side effects, expand education and awareness initiatives among healthcare providers and patients, and push for collaborative efforts in clinical trials to assess the long-term efficacy and safety of treatments. Innovation can thrive in areas like digital health tools for monitoring disease progression, the integration of AI in diagnostic precision, and the development of non-invasive therapies. Thus, while the axSpA market presents challenges, it simultaneously offers tangible opportunities for breakthroughs that can redefine patient care and market dynamics.

KEY MARKET STATISTICS
Base Year [2023] USD 5.32 billion
Estimated Year [2024] USD 5.68 billion
Forecast Year [2030] USD 8.79 billion
CAGR (%) 7.42%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Axial Spondyloarthritis Market

The Axial Spondyloarthritis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of arthritis and joint pain
    • Growing number of research and development activities
    • Efforts by government and private players to expand treatment options for arthritis
  • Market Restraints
    • Incidences of product and drug recall
  • Market Opportunities
    • Advances in personalized care for axial spondyloarthritis
    • Emergence of novel biologic agents targeting axial spondyloarthritis
  • Market Challenges
    • Stringent regulations concerning the drug approval process

Porter's Five Forces: A Strategic Tool for Navigating the Axial Spondyloarthritis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Axial Spondyloarthritis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Axial Spondyloarthritis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Axial Spondyloarthritis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Axial Spondyloarthritis Market

A detailed market share analysis in the Axial Spondyloarthritis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Axial Spondyloarthritis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Axial Spondyloarthritis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Axial Spondyloarthritis Market

A strategic analysis of the Axial Spondyloarthritis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Axial Spondyloarthritis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., Eli Lilly and Company, Galapagos NV, Inmagene Biopharmaceuticals, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Axial Spondyloarthritis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Ankylosing Spondylitis (AS) and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)).
  • Based on Drug Class, market is studied across Anti-Rheumatic Drugs, Glucocorticoids, and Non-steroidal anti-inflammatory Drugs (NSAIDs).
  • Based on End User, market is studied across Academic Research Institutes, Clinics, Hospital, and Rehabilitation Center.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of arthritis and joint pain
      • 5.1.1.2. Growing number of research and development activities
      • 5.1.1.3. Efforts by government and private players to expand treatment options for arthritis
    • 5.1.2. Restraints
      • 5.1.2.1. Incidences of product and drug recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Advances in personalized care for axial spondyloarthritis
      • 5.1.3.2. Emergence of novel biologic agents targeting axial spondyloarthritis
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations concerning the drug approval process
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Axial Spondyloarthritis Market, by Type

  • 6.1. Introduction
  • 6.2. Ankylosing Spondylitis (AS)
  • 6.3. Non-Radiographic Axial Spondyloarthritis (nr-axSpA))

7. Axial Spondyloarthritis Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Anti-Rheumatic Drugs
  • 7.3. Glucocorticoids
  • 7.4. Non-steroidal anti-inflammatory Drugs (NSAIDs)

8. Axial Spondyloarthritis Market, by End User

  • 8.1. Introduction
  • 8.2. Academic Research Institutes
  • 8.3. Clinics
  • 8.4. Hospital
  • 8.5. Rehabilitation Center

9. Americas Axial Spondyloarthritis Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Axial Spondyloarthritis Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Axial Spondyloarthritis Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Amgen Inc.
  • 4. Eli Lilly and Company
  • 5. Galapagos NV
  • 6. Inmagene Biopharmaceuticals
  • 7. Johnson & Johnson Services, Inc.
  • 8. Merck & Co., Inc.
  • 9. Novartis AG
  • 10. Pfizer Inc.
  • 11. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. AXIAL SPONDYLOARTHRITIS MARKET RESEARCH PROCESS
  • FIGURE 2. AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AXIAL SPONDYLOARTHRITIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. AXIAL SPONDYLOARTHRITIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AXIAL SPONDYLOARTHRITIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AXIAL SPONDYLOARTHRITIS MARKET DYNAMICS
  • TABLE 7. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ANKYLOSING SPONDYLITIS (AS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA)), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ANTI-RHEUMATIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY GLUCOCORTICOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY REHABILITATION CENTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM AXIAL SPONDYLOARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. AXIAL SPONDYLOARTHRITIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. AXIAL SPONDYLOARTHRITIS MARKET, FPNV POSITIONING MATRIX, 2023